BioSpace News Archive

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity “Horizons in Oncology” virtual conference on April 15, 2021.

City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and CytoImmune Therapeutics Inc. (“CytoImmune”), a clinical-stage biopharmaceutical company focused on commercializing novel cancer immunotherapy products, announced that they have entered into worldwide exclusive license agreements.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today reported initial data indicating that a single subcutaneous injection of the company’s COVID-19 vaccine candidate in healthy Phase 1 clinical study participants stimulates the generation of T cells that are reactive to the spike (S) and nucleocapsid (N) protein antigens delivered by the vaccine

SightCall, an augmented reality (AR)-powered visual assistance platform, today announced its partnership with Stago Group, a multinational developer of haemostasis solutions for diagnostic laboratories

HE Capital will also provide other media communications services to raise the company’s overall corporate profile in North America and Europe.

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to eprenetapopt for treatment of AML.

Tricida, Inc. announced that it will present at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 12:45 pm PT / 3:45 pm ET.

Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC Business Daily

Cresilon, Inc., the Brooklyn -based biotechnology company, announced today the successful close of its Series A-3 financing, totaling $38.5 million . This financing is expected to allow the company to aggressively accelerate its global growth plan and expand the rollout of VETIGEL ®

On the back of a successful partnership that started just over one year ago, the owners of Prince Premium+ Nitrile Exam Gloves (GIS RESOURCES SDN BHD) announced a distribution agreement with Tristate Medical Supplies - a leading distributor of medical supplies to the United States Government.